Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that FLT3-ITD status confers therapeutic sensitivity to Cytarabine, Daunorubicin, Quizartinib in patients with Acute Myeloid Leukemia.
The Republic of Ireland's Health Service Executive (HSE) has approved quizartinib in combination with standard daunorubicin and cytarabine induction therapy for reimbursement as a treatment option for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.
This statement is based on a regulatory approval from the Health Service Executive:
Quizartinib in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2025-02-01 | Health Service Executive | Indication approved for reimbursement. |
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |